NO20002965L - Antihyperlipidemisk statin-LP(a) inhibitor kombinasjoner - Google Patents

Antihyperlipidemisk statin-LP(a) inhibitor kombinasjoner

Info

Publication number
NO20002965L
NO20002965L NO20002965A NO20002965A NO20002965L NO 20002965 L NO20002965 L NO 20002965L NO 20002965 A NO20002965 A NO 20002965A NO 20002965 A NO20002965 A NO 20002965A NO 20002965 L NO20002965 L NO 20002965L
Authority
NO
Norway
Prior art keywords
antihyperlipidemic
statin
inhibitor combinations
inhibitor
combinations
Prior art date
Application number
NO20002965A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002965D0 (no
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Randy Ranjee Ramharack
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20002965D0 publication Critical patent/NO20002965D0/no
Publication of NO20002965L publication Critical patent/NO20002965L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20002965A 1997-12-12 2000-06-09 Antihyperlipidemisk statin-LP(a) inhibitor kombinasjoner NO20002965L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
PCT/US1998/023480 WO1999030706A1 (en) 1997-12-12 1998-11-04 ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS

Publications (2)

Publication Number Publication Date
NO20002965D0 NO20002965D0 (no) 2000-06-09
NO20002965L true NO20002965L (no) 2000-06-09

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002965A NO20002965L (no) 1997-12-12 2000-06-09 Antihyperlipidemisk statin-LP(a) inhibitor kombinasjoner

Country Status (14)

Country Link
EP (1) EP1037623A1 (enExample)
JP (1) JP2003524582A (enExample)
KR (1) KR20010033017A (enExample)
AU (2) AU1306099A (enExample)
BR (1) BR9813539A (enExample)
CA (1) CA2299397A1 (enExample)
HU (1) HUP0100349A3 (enExample)
IL (1) IL134364A0 (enExample)
IS (1) IS5385A (enExample)
NO (1) NO20002965L (enExample)
NZ (1) NZ502874A (enExample)
PL (1) PL343851A1 (enExample)
WO (1) WO1999030706A1 (enExample)
ZA (1) ZA9811349B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
CA2396157A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
CA2399396A1 (en) * 2000-02-10 2001-08-16 Yasuo Sugiyama Tnf- .alpha. inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
WO1993013801A1 (en) * 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
EP0627917A1 (en) * 1992-02-25 1994-12-14 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
AU732465B2 (en) * 1996-04-17 2001-04-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
AU1306099A (en) 1999-07-05
AU2003244047A1 (en) 2003-09-25
PL343851A1 (en) 2001-09-10
CA2299397A1 (en) 1999-06-24
NO20002965D0 (no) 2000-06-09
IL134364A0 (en) 2001-04-30
HUP0100349A2 (hu) 2001-07-30
JP2003524582A (ja) 2003-08-19
EP1037623A1 (en) 2000-09-27
IS5385A (is) 2000-02-25
BR9813539A (pt) 2000-10-10
WO1999030706A1 (en) 1999-06-24
ZA9811349B (en) 1999-06-14
HUP0100349A3 (en) 2002-02-28
NZ502874A (en) 2004-03-26
KR20010033017A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
ID24931A (id) Dipeptida nitril
FI973544A0 (fi) Foerfarande foer att foermedla meddelanden
FI973718A0 (fi) Foerbaettrat foerfarande foer att byta basstation
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
NO20003256D0 (no) ACE inhibitor-MMP inhibitor kombinasjoner
NO20002659D0 (no) Trombinreseptorantagonister
DE69821569D1 (de) Tetraederinterpolation
ID20285A (id) Katrol tangan
DE19756119B4 (de) Heftvorrichtung
FR2768938B1 (fr) Raquette a neige
FR2760375B1 (fr) Raquette a neige
DE69815029D1 (de) Heftvorrichtung
DE69812851D1 (de) Heftvorrichtung
DE59811177D1 (de) Mikrowellen-Bauelement
NO20002965L (no) Antihyperlipidemisk statin-LP(a) inhibitor kombinasjoner
FI974260A0 (fi) Foerfarande foer att foermedla en kvittering till en A-abonnent
NO995005L (no) En ny fremgangsmåte
FR2762977B1 (fr) Table a rallonges
DE19882544T1 (de) Verbesserungen bei Jojos
DE69805245D1 (de) Heftvorrichtung
EP1007548A4 (en) THROMBIN INHIBITOR FROM TSE-TSE FLY
FI973568A0 (fi) Foerfarande foer att foerhindra sintring i en virvelbaedd
DE59709933D1 (de) Leiterplattenprüfvorrichtung
DE59809440D1 (de) Mikrowellen-Bauelement

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application